FDA
-
-
-
-
-
-
-
Neurogene Highlights Data at ASGCT Meeting Supporting Therapeutic Rationale for ICV Delivery Method in CNS-targeted Gene Therapy
-
-
-
-
-
-
-
Neurogene Announces Recent Achievements and Anticipated 2026 Key Milestones for NGN-401, a Potential Best-in-Class Gene Therapy for Rett Syndrome
-
-
-
-
-
-
-
Stifel Reiterates Buy Rating on Neurogene (NGNE)
-
-
-
-
-
-
-
Neurogene (NGNE) PT Raised to $22 at BMO Capital
-
-
-
-
-
-
-
H.C. Wainwright Reiterates Buy Rating on Neurogene (NGNE)
-
-
-
-
-
-
-
Neurogene (NGNE) Reports Positive Interim Efficacy Data from First Four Low-Dose Pediatric Participants in NGN-401 Gene Therapy Clinical Trial for Rett Syndrome
-
-
-
-
-
-
-
Neurogene Announces Addition to Russell 3000® Index
-
325,594 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

